Results 211 to 220 of about 301,643 (264)

Successful immunosuppressive drug-free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report. [PDF]

Clin Case Rep
Palomo Bravo Á, Prieto Bonilla R, Bardan Rebollar D, López-Jaime FJ, Fernández-Bello I.   +4 more
europepmc   +1 more source

Protein S antibody as an adjunct therapy for hemophilia B. [PDF]

Blood Adv
Wilson HP, Pierre A, Paysse AL, Kumar N, Cooley BC, Rudra P, Dorsey AW, Polania-Villanueva D, Chatterjee S, Janbain M, Velez MC, Majumder R.   +11 more
europepmc   +1 more source

Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States. [PDF]

J Manag Care Spec Pharm
Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S.   +5 more
europepmc   +1 more source

Clinical analysis and quality of life survey of hemophilia B patients in the central and western regions of China. [PDF]

Front Pediatr
Wang W, Xu L, Wu J, Liu W, Jin J, Huang J, Xu Z, Huang Y, Li B, Liu Y, Zhang Q, Zhou M, Peng J, Hu Q.   +13 more
europepmc   +1 more source

Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.

Blood
Lee K, Chau JQ, Suber YB, Sternberg AR, Pishko AM, George LA, Bhoj VG, Doshi BS, Samelson-Jones BJ.   +8 more
europepmc   +1 more source

Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management. [PDF]

Clin Case Rep
Benitez-Hidalgo O, Suito Alcántara M, Martinez Garcia MF, Campoy D, Olivera P, Gironella Mesa M, Juarez-Gimenez JC.   +6 more
europepmc   +1 more source

Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B. [PDF]

J Manag Care Spec Pharm
Pauly N, Burrell A, Drelich D, Zhang X, Thiruvillakkat K, Nysenbaum J, Fiori A, Yan S.   +7 more
europepmc   +1 more source

The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B. [PDF]

J Manag Care Spec Pharm
Sarker J, Tice JA, Rind DM, Pearson SD, Walton SM.   +4 more
europepmc   +1 more source

HEPATOCYTE TRANSPLANTATION: A POTENTIAL NEW THERAPY FOR HEMOPHILIA B

, 2008
Kazuhiko Ohashi, Kumiko Tatsumi, Masami Shima, Yosuke Nakajima, Akira Yoshioka, Teruo Okano   +5 more
openalex   +1 more source